| Benita Daniel, | |
|
14502 W Meeker Blvd, Sun City, AZ 85375-5282 | |
| (623) 524-6550 | |
| Not Available |
| Full Name | Benita Daniel |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 14502 W Meeker Blvd, Sun City, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457828006 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | S022834 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Benita Daniel, 14502 W Meeker Blvd, Sun City, AZ 85375-5282 Ph: (623) 524-6550 | Benita Daniel, 14502 W Meeker Blvd, Sun City, AZ 85375-5282 Ph: (623) 524-6550 |
News Archive
Survivors of early-stage lung cancer who take part in regular physical activity have a better quality of life, according to a study in the February issue of the journal Cancer Epidemiology Biomarkers and Prevention , available online now.
Men and women with major depressive disorder have opposite changes in the expression of the same genes, according to a new postmortem brain study by researchers at the University of Pittsburgh and Centre for Addiction and Mental Health, Toronto, Canada.
In response to the healthcare reform legislation that was signed into law this week, the American Academy of Pain Medicine, in a statement released today, voiced its strong support of certain components of the reform legislation that will "improve the quality of life for people who suffer with chronic and acute pain."
DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.
Pharmasset, Inc. announced today that dosing has begun in Part 2 of a Phase 1 study. This is the first clinical study combining a purine (PSI-938) and a pyrimidine (PSI-7977) nucleotide analog for HCV, and is designed to evaluate once daily doses of PSI-7977 and PSI-938 in patients with HCV who have not been treated previously.
› Verified 7 days ago
Mr. Kandarp D Patel, R. PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14806 N Del Webb Blvd, Sun City, AZ 85351 Phone: 602-266-0021 Fax: 602-266-0068 | |
Daljinder Sidhu, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10707 W Peoria Ave, Sun City, AZ 85351 Phone: 623-974-3603 | |
Cindy Neroni I, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15442 N 99th Ave, Sun City, AZ 85351 Phone: 623-974-2526 | |
Kimberly Briones Albright, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10401 W Thunderbird Blvd, Sun City, AZ 85351 Phone: 623-832-2080 | |
Christi Jen, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10401 W Thunderbird Blvd, Banner Boswell Medical Center Dept Of Pharmacy, Sun City, AZ 85351 Phone: 623-832-4746 | |
Timothy Scott Engle, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15442 N 99th Ave, Sun City, AZ 85351 Phone: 623-974-2526 Fax: 623-974-1554 | |
Grace Ting Ancheta, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 13041 N Del Webb Blvd, Sun City, AZ 85351 Phone: 623-876-2216 Fax: 623-876-2123 |